ACCURAY WKN: A0MKWM ISIN: US0043971052 Kürzel: XEJ Forum: Aktien Thema: Hauptdiskussion
1,785 EUR
+0,85 %+0,015
23. Dec, 17:49:34 Uhr,
Lang & Schwarz
Kommentare 259
MrTraxxas,
19.09.2022 20:04 Uhr
0
Ich finde das man genug Informationen erhält und es stimmen auch die Zahlen.
Ein gutes Unternehmen für die Zukunft
MrTraxxas,
19.09.2022 16:19 Uhr
1
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00517-4/fulltext
Summer.76,
07.09.2022 15:37 Uhr
1
Accuray Partners with Swiss-based Genolier Innovation Hub to Bring Medical and Technological Advances to Patients Faster
https://www.prnewswire.com/news-releases/accuray-partners-with-swiss-based-genolier-innovation-hub-to-bring-medical-and-technological-advances-to-patients-faster-301618994.html
MrTraxxas,
11.08.2022 16:11 Uhr
1
Na sie lebt noch
Summer.76,
11.08.2022 5:58 Uhr
0
Accuray rises 5% following fiscal 2022 Q4 beats, fY 2023 revenue range within consensus
https://seekingalpha.com/news/3871144-accuray-rises-5-following-fiscal-2022-q4-beats-fy-2023-revenue-range-within-consensus
• Accuray Inc. (NASDAQ:ARAY) is up 5% in after-hours trading after reporting fiscal 2022 Q4 results that beat on the top and bottom lines and issuing a FY 2023 revenue estimate that falls within analyst consensus.
• The company projects FY 2023 revenue of $447M-$455M. The consensus estimate is $451.29M
• Adjusted EBITDA is expected in the range of $26 million to $30 million.
• Net loss of ~3.5M in the quarter was ~69% narrower compared to FQ4 2021.
• Revenue of $110.M was a ~1% year-over-year increase.
• Accuray ended the quarter with $88.7M in cash and cash equivalents, a 24% decline from the end of FQ4 2021.
Summer.76,
11.08.2022 5:58 Uhr
0
Accuray GAAP EPS of -$0.04 beats by $0.03, revenue of $110.02M beats by $4.7M
https://seekingalpha.com/news/3870996-accuray-gaap-eps-of-0_04-beats-0_03-revenue-of-110_02m-beats-4_7m
Summer.76,
11.08.2022 5:57 Uhr
0
Accuray Reports Fourth Quarter and Fiscal 2022 Financial Results
https://www.prnewswire.com/news-releases/accuray-reports-fourth-quarter-and-fiscal-2022-financial-results-301603116.html
8.5% FY22 revenue growth; Company issues guidance for FY23
MrTraxxas,
14.07.2022 11:31 Uhr
0
https://www.surgicalroboticstechnology.com/news/new-clinical-studies-show-benefits-of-accuray-cyberknife-in-treatment-of-neurological-indications/
MrTraxxas,
12.07.2022 17:18 Uhr
0
Sau 👍
Summer.76,
12.07.2022 15:49 Uhr
0
Accuray CyberKnife® System Real World Data and Clinical Studies Show Benefits in Treatment of Neurological
https://www.prnewswire.com/news-releases/accuray-cyberknife-system-real-world-data-and-clinical-studies-show-benefits-in-treatment-of-neurological-indications-301583528.html
Summer.76,
23.06.2022 16:27 Uhr
0
https://www.benzinga.com/quote/ARAY/analyst-ratings
Accuray Price Target Announced at $7.50/Share by B. Riley Securities
Summer.76,
02.06.2022 16:37 Uhr
1
Accuray and Limbus AI Inc. Partner to Leverage Limbus' Innovative AI-driven Technology to Enhance Accuray Adaptive Radiotherapy Solutions
https://www.prnewswire.com/news-releases/accuray-and-limbus-ai-inc-partner-to-leverage-limbus-innovative-ai-driven-technology-to-enhance-accuray-adaptive-radiotherapy-solutions-301559886.html
Partnership will Enable Accuray to Use Limbus' Technology to Streamline the Treatment Planning Process and Increase Operational Efficiency
Summer.76,
10.05.2022 16:24 Uhr
0
New Data Presented at ESTRO 2022 Reinforce Benefits of Accuray CyberKnife® and TomoTherapy® Platforms Across a Range of Indications and Complexities
https://www.prnewswire.com/news-releases/new-data-presented-at-estro-2022-reinforce-benefits-of-accuray-cyberknife-and-tomotherapy-platforms-across-a-range-of-indications-and-complexities-301543379.html
More Than 70 Abstracts Build on the Clinical Evidence Supporting the Use of These Technologies
Summer.76,
05.05.2022 15:50 Uhr
1
Accuray ClearRT™ Helical Fan-Beam kVCT Imaging Wins "Best New Technology Solution for Oncology" MedTech Breakthrough Award
https://www.prnewswire.com/news-releases/accuray-clearrt-helical-fan-beam-kvct-imaging-wins-best-new-technology-solution-for-oncology-medtech-breakthrough-award-301540539.html
Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies
Summer.76,
27.04.2022 22:17 Uhr
0
https://investors.accuray.com/news-releases/news-release-details/accuray-announces-suzanne-winter-president-promoted-president
Summer.76,
27.04.2022 22:08 Uhr
0
Accuray Reports Fiscal 2022 Third Quarter Financial Results
https://www.prnewswire.com/news-releases/accuray-reports-fiscal-2022-third-quarter-financial-results-301533954.html
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | ATOS Hauptdiskussion | +19,05 % | |
2 | MANZ Hauptdiskussion | -8,08 % | |
3 | BAYER Hauptdiskussion | -0,34 % | |
4 | Trading- und Aktien-Chat | ||
5 | NVIDIA Hauptdiskussion | +2,07 % | |
6 | TILRAY INC. CL.2 DL-,0001 Hauptdiskussion | +10,17 % | |
7 | für alle, die es ehrlich meinen beim Traden. | ||
8 | Aethlon Medical, Inc. | +12,68 % | |
9 | PROSIEBENSAT1 MEDIA Hauptdiskussion | -1,67 % | |
10 | Palantir ohne Schnickschnack | -0,09 % | Alle Diskussionen |
Aktien
|
Thema | ||
---|---|---|---|
1 | ATOS Hauptdiskussion | +19,05 % | |
2 | MANZ Hauptdiskussion | -8,08 % | |
3 | BAYER Hauptdiskussion | -0,34 % | |
4 | NVIDIA Hauptdiskussion | +2,07 % | |
5 | TILRAY INC. CL.2 DL-,0001 Hauptdiskussion | +10,17 % | |
6 | Aethlon Medical, Inc. | +12,68 % | |
7 | PROSIEBENSAT1 MEDIA Hauptdiskussion | -1,67 % | |
8 | Palantir ohne Schnickschnack | -0,09 % | |
9 | FREYR BATTERY | ±0,00 % | |
10 | Polestar Automotive | +4,69 % | Alle Diskussionen |